The first wave of investigation conducted with GBM stem cells (GBM-SCs) suggested that only the CD133+ population was endowed with clonogenic ability and was able to recapitulate the parental disease after inoculation in immunocompromised mice. This evidence concerns the gene PROM1 and glioblastoma.